Home Blog Page 73

BingX Strengthens Market Confidence with Dedicated Trust Center

By
Advertorial Desk
-

Dedicated Trust Center brings together BingX’s Proof of Reserves, $150 million Shield Fund, internationally certified security standards, and eight-year track record of operations.

PANAMA CITY, July 30, 2026 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3-AI company, has launched its dedicated Trust Center exhibiting the platform’s security framework, asset transparency, and long-term operational milestones. The initiative reflects BingX’s continued investment in building a resilient platform trusted by more than 40 million users worldwide.


As trust and transparency become increasingly important across the broader industry, BingX continues to strengthen the foundations that support its long-term growth. Over the past eight years, BingX has focused on building trust through consistent operations, transparent asset protection, robust risk management, and a user-first approach.

“Trust is not established overnight, but earned through consistent transparency, reliable operations, and an unwavering commitment to users,” said Pablo Monti, Spokesperson of BingX. “Every milestone, from Proof of Reserves and global compliance to strategic partnerships and product innovation, reflects our commitment to building a platform users can rely on for the long term.”

Building Trust Through Transparency and Security

The platform’s trust framework includes 100% Proof of Reserves through monthly Merkle Tree snapshots. According to the latest reserve report on July 15, 2026, BingX maintains a BTC reserve ratio of 142.82%, an ETH reserve ratio of 126.48%, a USDT reserve ratio of 131.83%, and a USDC reserve ratio of 124.41%, demonstrating full backing of user assets.

BingX further strengthens user protection through a US$150 million Shield Fund, together with multi-layer asset protection, multi-signature authorization, tiered cold, warm and hot wallet architecture, real-time risk monitoring and 24/7 global customer support.

The platform has also achieved internationally recognized PCI DSS 4.0.1 and ISO/IEC 27001 certifications, validating its controls across information protection, risk management, operational resilience, and incident response. Regular third-party security assessments further reinforce BingX’s commitment to maintaining a secure trading environment.

Expanding Presence Through Compliance and Innovation

Alongside its security framework, BingX continues to expand its global footprint through regulatory progress and product innovation.

The company has advanced its presence in Europe, where BingX EU has submitted an application for authorisation as a crypto-asset service provider on MiCAR, reinforcing its commitment to compliant growth.

BingX is also continuing its evolution into a leading multi-asset trading platform. Through BingX TradFi, eligible users can access traditional financial markets—including stocks, commodities, forex and indices—alongside cryptocurrencies, with products available subject to regional regulations and eligibility requirements.

Trusted by Global Partnerships

BingX’s long-term commitment to trust extends beyond its platform through partnerships with globally recognized organizations, reinforcing its credibility and strengthening its presence across international markets.

Its partnership with Chelsea Football Club has continued to grow over the past two years, evolving from Official Sleeve Partner to Official Training Wear Partner and featuring global initiatives such as the “Trained on Greatness” campaign. In 2026, BingX also renewed the  partnership, extending a collaboration founded on shared values of discipline, excellence, and continuous improvement.

In 2026, BingX also became Scuderia Ferrari HP’s first-ever crypto exchange partner. The multi-year partnership brings together two global brands built around performance, innovation, and delivering unique experiences to users around the world.

Responsibility Beyond Trading

BingX believes trust is built not only through technology and security, but also through meaningful contributions to society.

Supported by a $10 million BingX Charity Fund, the company has contributed to humanitarian relief, education, environmental sustainability, and community development initiatives since 2022. Recent initiatives include a year-long partnership with Save the Children supporting vulnerable children in Bosnia and Herzegovina, disaster relief efforts across Asia, support for communities affected by the 2025 fires in Hong Kong and ongoing educational and environmental programs worldwide.

Through BingX Charity, the company translates its global reach into tangible support for people, communities, and environmental causes worldwide.

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3-AI company, serving over 40 million users worldwide. Ranked among the top five global crypto derivatives exchanges and a pioneer of crypto copy trading, BingX addresses the evolving needs of users across all experience levels.

Powered by a comprehensive suite of AI-driven products and services, including futures, spot, copy trading, and TradFi offerings, BingX empowers users with innovative tools designed to enhance performance, confidence, and efficiency.

BingX has been the principal partner of Chelsea FC since 2024, and became the first official crypto exchange partner of Scuderia Ferrari HP in 2026.

For more information, please visit: https://bingx.com/

 

 

Liaoning: Where Industrial Grit Meets Untamed Wilderness

By
Advertorial Desk
-

SHENYANG, China, July 30, 2026 /PRNewswire/ — Nestled in the strategic gateway to northeastern China, Liaoning is home to a civilization spanning more than 5,000 years. The Niuheliang Hongshan culture site marks the dawn of Chinese prehistoric civilization. The Shenyang Imperial Palace and the Great Wall on the water preserve the legacy of the Ming and Qing dynasties, while intangible cultural heritage such as Xiuyan jade carving and Manchu paper-cutting carries forward the spirit of Eastern craftsmanship.


Liaoning: Where Industrial Grit Meets Untamed Wilderness

As the cradle of the People’s Republic of China’s industry, this land once formed the backbone of the nation’s industrial development. Today, it is being revitalized through smart manufacturing and digital transformation. The Bohai Bay coastline, the Red Beach wetlands, and snow-covered forests create the distinctive scenery of northern China, where rugged warmth and an open spirit coexist. Breaking free from stereotypes, this land—rich in history and vibrant with innovation—is opening its doors to the world with a dynamic and multifaceted identity.

EQT to sell Quantios, a leading provider of SaaS solutions to the global Trust and Corporate Services industry, to Vista Equity Partners

By
Advertorial Desk
-
  • During EQT’s ownership, Quantios evolved into a global software platform serving close to 700 organizations worldwide through the combination of ViewPoint and TrustQuay
  • EQT supported Quantios’ transformation through cloud migration, AI innovation and product expansion, including the launch of Quantios Core and the acquisition of Klea
  • The transaction demonstrates EQT’s strategy of partnering with founder-led and mid-market technology companies to build stronger, more global businesses through active ownership, strategic M&A and value creation

SYDNEY, July 30, 2026 /PRNewswire/ — EQT today announced that the EQT Private Capital Asia Mid-Market Opportunities Fund I (“EQT”) has agreed to sell its stake in Quantios, a leading provider of SaaS solutions to the globalTrust and Corporate Services industry, to Vista Equity Partners. 

EQT initially partnered with the founders of Malaysia-based ViewPoint in 2023 to support the company’s next stage of growth. During EQT’s ownership, ViewPoint combined with TrustQuay (backed by technology investor, HG) to create Quantios, bringing together two highly complementary businesses to build a global software platform serving close to 700 organizations worldwide. Today, Quantios supports customers across more than 100 jurisdictions with software that helps streamline complex trust and corporate administration workflows.

Working alongside the management team, EQT supported Quantios’ transformation through the launch of Quantios Core, a cloud-native SaaS platform that modernized customer workflows and accelerated the transition from on-premise software to a subscription-based model. The business also strengthened its AI capabilities and expanded into new customer segments through the acquisition of Klea, an AI-powered legal entity management platform for corporate legal departments. 

Nicholas Macksey, Co-Head of EQT Private Capital Asia and Head of Asia’s Mid-Market strategy, said: “The successful exit of Quantios is an important milestone for our Asia mid-market strategy. It demonstrates our ability to create value through active ownership and deliver successful outcomes, even in a more selective market for software transactions this year. Asia Pacific continues to offer compelling opportunities for high-quality mid-market companies, and we believe EQT’s sector expertise, operational capabilities, and global network position us well to help founders and management teams accelerate their next stage of growth.” 

Jacob Van der Wiel, Managing Director within EQT Private Capital Asia’s Mid-Market strategy, said: “When we invested in ViewPoint, we saw the opportunity to partner with an ambitious founder and build a global software platform. Through the combination with TrustQuay, continued investment in an AI-powered next-generation cloud platform, and the strategic acquisition of Klea, Quantios has evolved into a stronger, more diversified business with global reach. We’re proud of what we have accomplished together and believe the company is well-positioned for continued success in its next chapter.”

Guy Harrison, Chief Executive Officer of Quantios, said: “Since partnering with EQT and Hg, we’ve transformed two specialist software businesses into a scaled, integrated platform serving hundreds of customers across the Trust and Corporate Services sector. We’ve expanded internationally, accelerated product development and helped our customers navigate two of the biggest technology shifts our industry has seen: first the move to cloud, and now agentic. I’m incredibly proud of what the team has achieved and grateful to EQT and Hg for their support and partnership. We’ve built a fantastic business and I’m excited about the next phase of growth alongside Vista.”

The successful transformation and exit of Quantios highlights the momentum of EQT Private Capital Asia’s mid-market strategy, which complements the firm’s flagship large-cap strategy by partnering with high-quality businesses across Asia Pacific. 

The transaction is subject to customary conditions and approvals and is expected to be completed in Q3 2026.

Contact:
EQT Press Office, press@eqtpartners.co

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-sell-quantios–a-leading-provider-of-saas-solutions-to-the-global-trust-and-corporate-service,c4378419

The following files are available for download:

https://mb.cision.com/Main/87/4378419/4205665.pdf

260729 EQT to sell Quantios, a leading provider of SaaS solutions to the global Trust and Corporate Services industry, to Vista Equity Partners

https://news.cision.com/eqt/i/quantios,c3555186

Quantios

Investor Pointe Names Manfredi Bargioni Chief Client Officer

By
Advertorial Desk
-

Untap co-founder will lead expanded client success and services teams as the company deepens its focus on client outcomes across private markets.

London, United Kingdom – Newsfile Corp. – July 29, 2026 – Investor Pointe, a global technology and services firm powering how private markets firms operate, today announced the appointment of Manfredi Bargioni as Chief Client Officer. Bargioni will lead Investor Pointe’s client success and services teams. The appointment reflects the company’s approach of providing human expertise and agentic technology at the level each organisation requires.

A co-founder of Untap, which is now part of Investor Pointe, Bargioni brings more than 20 years of experience in financial services and business development, including senior leadership roles at Citigroup and UBS, as well as serving as COO of Hydra Management. His teams help private markets investment managers, wealth managers, advisors, and fund administrators realise the full value of their technology, operations, and data. He will oversee clients globally and is based in the company’s London office.

Drawing on Bargioni’s experience across firms of varying sizes, technology demands, and data maturity, the expanded function provides clients with local expertise supported by a multijurisdictional technology platform. The function is centred around regional leaders: Harriet Barlow and Olivia Gibson in EMEA, Claudia Madriaga in South America, Max Fenn in APAC, and Jay Shows in North America. Their teams assist clients with a full range of services spanning the firm’s solutions, with specialists in account management, investor servicing, and implementation.

“For us, client success encompasses the entire relationship: the product roadmap, the services we provide, and the challenges we address together,” said Bargioni. “We want every client to realise the full value of their technology and, above all, their data. Their success is our success, and we see ourselves as an extension of their team. Self-service, co-managed, or fully managed, we handle as much of fund operations, investor relations, and data workflows as they want us to, so their people stay focused on relationships and returns.”

“Private markets firms are facing rising investor demand for real-time reporting and transparency, even as much of the industry’s data still lives in spreadsheets and disconnected systems,” said Scott Hofmann, Investor Pointe CEO. “Our model combines AI-powered technology with a dedicated services team so firms can close that gap without having to develop the capability in-house. Client success has been a key differentiator for us from the start, and this new role reflects that. Manfredi’s extensive experience, closely aligned with how private markets firms actually operate, provides the perspective we need to achieve positive client outcomes, and that’s why he’s the right person for the job as we grow.”

About Investor Pointe: Investor Pointe is a global technology and services firm powering how private markets firms operate. It unites distribution, investor engagement, portfolio management, and the underlying data layers into a single, secure system. As a partner from initial product decisions to the final capital return, Investor Pointe’s agentic solution is supported by a team of human experts to provide clients with exactly the level of support they need, from self-serve to fully managed. Investor Pointe has over 2,500 funds managed on its system, working with leading investment managers, wealth managers, fund administrators, and advisors with over $400 billion in assets. Investor Pointe has offices in London, New York, Hong Kong, Hyderabad, and Bogotá. For more information, visit www.investorpointe.com.

Press Contact:
Margarita Kouklaki Ntourou
Communications Manager, Investor Pointe
margarita.kouklakintourou@investorpointe.com

The issuer is solely responsible for the content of this announcement.

Pacific Century Premium Developments Limited announces interim results for six months ended June 30, 2026

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 29 July 2026

2026 Interim Results – Financial Highlights

(Figures for the corresponding period in 2025 are shown in brackets)

  • Consolidated revenue: HK$593 million (HK$ 636 million)
  • Consolidated net loss attributable to equity holders of the Company: HK$189 million (HK$ 249 million)
  • Basic loss per share: 9.28 HK cents (12.23 HK cents)
  • No interim dividend (No interim dividend)

Pacific Century Premium Developments Limited (“PCPD”, SEHK: 00432) announced its interim results for the six months ended June 30, 2026.

The consolidated revenue of PCPD and its subsidiaries (together, the “Group”) amounted to HK$ 593 million, compared to HK$ 636 million for the corresponding period of 2025.

The Group’s consolidated loss attributable to equity holders of the Company for the first six months of 2026 totalled HK$ 189 million, compared to a net loss of HK$249 million for the corresponding period last year. Basic loss per share for the six months ended June 30, 2026 was 9.28 Hong Kong cents, compared to a loss per share of 12.23 Hong Kong cents for the corresponding period of 2025.

The Board of Directors did not declare an interim dividend for the first half of 2026.

For the first half of 2026, the Group delivered encouraging results as we built on our core strengths and benefited from resilient demand across the markets in which we operate. During the period, we also took steps to enhance our portfolio, including the disposals of two investment assets. These initiatives are expected to strengthen the Group’s financial position and reinforce its long-term growth.

Our operations in Japan performed well despite some moderation in tourism demand, shaped by changes in the composition of international visitors and fluctuations in travel demand. Park Hyatt Niseko, Hanazono, our hospitality business in Niseko, Hokkaido, delivered a stable performance with healthy occupancy and room rates, while our ski operations remained a key contributor to the Group’s results. Earnings from our recreational facilities, ski lifts, equipment rentals, “Hanazono EDGE” (a restaurant and entertainment centre) and Niseko International Snowsports Schoolcontinued togrow year-on-year. We will stay focused on establishing Niseko Hanazono Resort as a world-class, all-season luxury destination and remain optimistic about its long-term development.

On March 16, 2026, the Group announced the sale of its entire interest in Pacific Century Place, Jakarta (“PCP Jakarta”) in Indonesia. The transaction, at a total consideration of US$400 million, was completed on June 8, 2026. Notwithstanding the disposal, the Group will continue to provide property management services in respect of PCP Jakarta.

On February 13, 2026, the Group announced the sale of its entire interest in Midtown Niseko. The transaction, at a total consideration of US$80 million, was completed on May 31, 2026.

The Group formed a strategic alliance with Hotel Properties Limited in Singapore to bring a Four Seasons Resort and Branded Residences to Aquella, a large-scale integrated resort development in Phang Nga. The move represents a significant milestone in PCPD‘s long-term vision of transforming Aquella into an integrated resort destination that effortlessly blends luxury living, recreation and exceptional service.

Central Residence by the Park in Hong Kong was launched for sale in January 2026. As at the end of June, 90.9% of the total available units of the luxury residential project had already been sold. The project will be completed in the latter half of 2026.

Mr. Benjamin Lam, PCPD’s Deputy Chairman and Group Managing Director, said: “The first half of 2026 presented a challenging global environment, characterised by geopolitical tensions including the conflict in the Middle East, inflation, trade uncertainties and concerns over monetary policies. Despite the headwinds, global growth was relatively resilient, while international tourism in many parts of Asia continued to perform steadily. The Group’s core markets in Asia generally remained solid during the period. Tourism demand continued to support Japan and Thailand despite a slightly more measured pace of growth. Improving sentiment in Hong Kong’s property market also provided a more favourable backdrop for our luxury residential development.

In the second half of the year, we will continue to enhance the value of our existing assets while positioning the Group to capitalise on opportunities that support our long-term strategy and create value for our stakeholders.”

Hashtag: #PacificCenturyPremiumDevelopments

The issuer is solely responsible for the content of this announcement.

About PCPD

Pacific Century Premium Developments Limited (“PCPD” or the “Group”, SEHK: 00432) is principally engaged in the development and management of premium-grade property and infrastructure projects as well as premium-grade property investments. PCCW Limited (“PCCW”, SEHK: 00008) is the single largest shareholder of the Group.

SEMI Reports Worldwide Silicon Wafer Shipments Increase 7.4% Year-on-Year in Q2 2026

By
Advertorial Desk
-

Growth in Global Silicon Wafer Shipments Driven by AI Demand as Industrial and Automotive Markets Show Signs of Recovery

MILPITAS, Calif., July 29, 2026 /PRNewswire/ — The SEMI Silicon Manufacturers Group (SMG) reported today, in its quarterly analysis of the silicon wafer industry, that worldwide silicon wafer shipments increased 7.4% year-on-year to 3,573 million square inches (MSI) from the 3,327 MSI recorded during the same quarter of 2025. Shipments increased 9.1% quarter-over-quarter from the 3,275 MSI recorded during the first quarter of 2026.

Worldwide Silicon Wafer Shipments
Worldwide Silicon Wafer Shipments

“Silicon wafer shipments maintained steady growth in the second quarter, driven by strong and increasing AI-related demand beyond advanced logic and memory to include power devices, photonics, and other markets,” said Ginji Yada, Chairman of SEMI SMG and Managing Executive Officer, General Manager, Sales and Marketing Division at SUMCO Corporation. “In addition, industrial and automotive demand is recovering, while memory price pressures are contributing to constrained PC and smartphone demand. Device manufacturers are investing heavily in capacity expansion, and silicon wafer demand growth is expected to continue.”

Silicon wafers are the fundamental building material for the majority of semiconductors, which are vital components of all electronic devices. The highly engineered thin disks are produced in diameters of up to 300 mm and serve as the substrate material on which most semiconductors are fabricated.

The SMG is a sub-committee of the SEMI Electronic Materials Group (EMG) and is open to SEMI members involved in manufacturing polycrystalline silicon, monocrystalline silicon or silicon wafers (e.g., as cut, polished, epitaxial). The SMG facilitates collective efforts on issues related to the silicon industry, including the development of statistics about the silicon industry.

For more information, visit SEMI Worldwide Silicon Wafer Shipment Statistics.

Follow SEMI Market Intelligence

Follow SEMI 

About SEMI

SEMI® is the global industry association connecting over 4,000 companies and 1.5 million professionals worldwide across the semiconductor and electronics design and manufacturing supply chain. We accelerate member collaboration on solutions to top industry challenges through Advocacy, Workforce Development, Sustainability, Supply Chain Management and other programs. Our SEMICON® expositions and events, technology communities, standards and market intelligence help advance our members’ business growth and innovations in design, devices, equipment, materials, services and software, enabling smarter, faster, more secure electronics. Visit www.semi.org, contact a regional office, and connect with SEMI on LinkedIn and X to learn more.

Association Contacts
Sherrie Gutierrez/SEMI
Phone: 1-831-889-3800
Email: sgutierrez@semi.org

Lisa Gillette-Martin/Bodewell Group (Media Inquiries)
Phone: 1-408-205-4732
Email: lgmartin@bodewellgroup.com   

SEMI® is the global industry association connecting over 4,000 companies and 1.5 million professionals worldwide across the semiconductor and electronics design and manufacturing supply chain. We accelerate member collaboration on solutions to top industry challenges through Advocacy, Workforce Development, Sustainability, Supply Chain Management and other programs. Our SEMICON® expositions and events, technology communities, standards and market intelligence help advance our members’ business growth and innovations in design, devices, equipment, materials, services and software, enabling smarter, faster, more secure electronics. Visit www.semi.org to learn more.
SEMI® is the global industry association connecting over 4,000 companies and 1.5 million professionals worldwide across the semiconductor and electronics design and manufacturing supply chain. We accelerate member collaboration on solutions to top industry challenges through Advocacy, Workforce Development, Sustainability, Supply Chain Management and other programs. Our SEMICON® expositions and events, technology communities, standards and market intelligence help advance our members’ business growth and innovations in design, devices, equipment, materials, services and software, enabling smarter, faster, more secure electronics. Visit www.semi.org to learn more.

COSRX secures multiple top-five Amazon rankings during Prime Day 2026

By
Advertorial Desk
-

NEW YORK, July 29, 2026 /PRNewswire/ — COSRX, the global derma skincare brand known for its essentials-only approach, announced today that it secured five top-five category placements on Amazon U.S. during Prime Day 2026, held from June 23 through June 26. Leading the impressive results, the Low pH Good Morning Gel Cleanser ranked No. 1 in Facial Cleansing Gels, while established icons and newer launches across facial serums, toners, eye masks and facial masks also rose to the top of their categories – showcasing the strength of the wider COSRX skincare lineup.

To explore the brand’s high-performance, results-driven skincare solutions, visit the official COSRX store on Amazon U.S.

COSRX secures multiple top-five Amazon rankings during Prime Day 2026
COSRX secures multiple top-five Amazon rankings during Prime Day 2026

Top-Performing COSRX Skincare Products on Prime Day 2026

Award-Winning Cleansers: Low pH Gel Tops Amazon Charts

The COSRX Low pH Good Morning Gel Cleanser led the brand’s Prime Day performance, reaching No. 1 in Amazon U.S.’s Facial Cleansing Gels category. Its lightweight gel formula washes away oil, sweat and daily impurities without leaving the skin feeling overly dry or tight. Because its low-pH formula is closer to the skin’s natural level, it provides a gentle, refreshing cleanse that fits easily into every day and sensitive-skincare routines. Frequently featured in K-beauty starter guides and must-buy lists, the cleanser has become a trusted introduction to Korean skincare as well as a longtime staple for users. With approximately 20,000 Amazon reviews and an average rating of 4.5 out of five stars, it remains one of COSRX’s most recognized and widely loved products.

Complementing the bestselling gel cleanser, the newer COSRX Red Rice Inositol Pore Clarifying Deep Cleanser recorded its highest sales volume since launch during Prime Day. Developed for clogged pores, blackheads, excess oil and rough texture, its dense, cushiony formula glides over the skin with a balm-like feel before transforming into a soft foam with water.

Together, the two cleansers offer a flexible AM-to-PM routine: a lightweight, low-pH gel for gentle daily cleansing and a richer pore cleanser when skin needs a more thorough reset.

Advanced Peptide Skincare for Anti-Aging and Radiance

COSRX’s Peptide-powered products delivered strong Prime Day results across both eye care and facial skincare. The Peptide Collagen Hydrogel Eye Patch ranked No. 2 in Amazon’s Eye Masks category, reinforcing its popularity as a viral TikTok favorite for visible puffiness, fine lines and loss of firmness. The cooling hydrogel patches combine peptides and collagen in an easy-to-use format that fits naturally into morning preparation or an evening self-care routine.

COSRX’s The 6 Peptide Skin Booster Serum also reached No. 2 in Amazon’s Facial Toners & Astringents category. The serum is a lightweight first-step booster with a toner-like texture, designed to prepare the skin for the products that follow while improving the look of texture, elasticity and radiance.

It was joined by the newly launched dermatologist-recommended Blue Peptide Bakuchiol Plump Glow Serum, which pairs naturally blue Copper Peptides (GHK-Cu) with the gentler Retinol-alternative Bakuchiol to help simultaneously plump, lift and refine the skin.

K-Beauty Staples: Snail Mucin and PDRN Formulas Dominate

Beyond Peptides, COSRX’s strength in clinically inspired, ingredient-led skincare was also reflected in the strong Prime Day performance of its Snail Mucin and PDRN formulas.

The Advanced Snail 96 Mucin Power Essence ranked No. 2 in Facial Serums and No. 25 across Amazon U.S. Beauty & Personal Care. Widely recognized as an original K-beauty icon, the essence has become a fixture on Amazon beauty must-buy lists, particularly during major deal events.

Its fast-absorbing Snail Mucin formula delivers lightweight hydration while helping support the skin barrier and calm the look of stressed, sun-exposed skin. The non-heavy texture makes it especially appealing during summer, leaving skin looking smoother, refreshed and luminous.

The PDRN EXOSOME Skinplaning Glaze Mask rounded out the rankings at No. 5 in Amazon’s Facial Masks category. The pearlescent Korean wrapping mask forms a luminous glaze as it dries, delivering intensive hydration and elasticity care before peeling away to reveal a smoother, more radiant-looking finish. With its PDRN-focused formula, eye-catching sheen and easy peel-off format, it offers an elevated at-home option for hydrated, glossy, glass-skin results.

About COSRX

Rooted in science and driven by results, COSRX is a global derma skincare brand known for its high-performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Amazon, ULTA, Revolve, Dermstore, Nordstrom and Target. Follow @cosrx on Instagram and TikTok for the latest product drops, tips, and trends.

Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

By
Advertorial Desk
-

Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies.

NANTONG, China, July 29, 2026 /PRNewswire/ — Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, today announced the successful closing of a new financing round exceeding $31 million (over RMB 200 million).

The round was led by Guozhong Capital, with participation from IDG Capital, China Everbright Limited, Jolmo Capital, Win-Win Capital, and SND Financial Holdings. Existing shareholder Longmen Capital participated for its third consecutive round.

Proceeds will primarily accelerate the clinical development of Ractigen’s saRNA assets and validate its proprietary extrahepatic delivery platforms. Key priorities include:

  • Advancing lead saRNA oncology program (RAG-01): Accelerating Phase 2 clinical trials in non-muscle-invasive bladder cancer (NMIBC) following positive clinical proof-of-concept and U.S. FDA Fast Track Designation.
  • Driving systemic saRNA asset toward IND (RAG-18): Advancing ongoing investigator-initiated trials (IIT) and preparing for IND filing for Duchenne muscular dystrophy (DMD).
  • Progressing CNS clinical asset (RAG-17): Moving forward with Phase 2 clinical trials in amyotrophic lateral sclerosis (ALS) following Phase 1 safety and biomarker validation published in Nature Medicine.
  • Expanding extrahepatic delivery platforms: Continuously enhancing the company’s proprietary SCAD™ (CNS) and LiCO™ (systemic multi-tissue) delivery technologies to unlock new therapeutic targets outside the liver.

Pioneering saRNA Technology: Unlocking Gene Activation for Unmet Needs

Oligonucleotide therapeutics represent the third major wave of biopharmaceutical innovation following small molecules and monoclonal antibodies. However, traditional RNA therapeutics have been largely limited to gene-silencing approaches (siRNA and ASO).

As the global pioneer in RNA activation (RNAa), Ractigen was founded to redefine genetic medicine by enabling precise gene activation. Discovered by Ractigen’s founder, RNAa utilizes saRNAs targeting gene promoter regions to upregulate endogenous protein expression at the transcriptional level without altering the genome. This unique mechanism unlocks previously undruggable therapeutic targets, expanding treatment possibilities across genetic disorders, haploinsufficiencies, cancer, and metabolic diseases.

Breaching Extrahepatic Barriers: Proprietary Delivery Systems

To deliver saRNA and targeted oligonucleotide payloads beyond the liver, Ractigen engineered two complementary, carrier-free delivery platforms:

  • SCAD™ (CNS delivery platform): Utilizes an accessory oligonucleotide (ACO)-enabled self-delivery mechanism to cross central nervous system barriers, achieving clinical proof-of-concept for safety and target engagement via RAG-17.
  • LiCO™ (Systemic multi-tissue platform): Conjugates specialized lipids to oligonucleotides via proprietary SDL™ linkers. LiCO™ enables durable, carrier-free delivery to muscle, heart, bladder, and eye tissues, sustaining therapeutic activity for up to nine months per single administration with simplified, cost-effective manufacturing.

Clinical & Commercial Momentum

Ractigen has successfully translated its saRNA and extrahepatic delivery technologies into three differentiated clinical-stage assets:

  • RAG-01: The world’s first conjugate-delivered saRNA therapeutic to demonstrate clinical proof-of-concept in oncology. In Phase 1 trials, RAG-01 achieved a preliminary any-time 67% complete response (CR) rate in BCG-unresponsive high-risk NMIBC patients.
  • RAG-18: The world’s first saRNA program targeting Duchenne muscular dystrophy (DMD) and a major milestone in breaching extrahepatic muscle delivery barriers. Currently in investigator-initiated trials (IIT), RAG-18 delivers saRNA systemically to upregulate Utrophin expression, demonstrating clear target engagement, marked biomarker reductions, and histopathological improvements in muscle tissue in DMD patients.
  • RAG-17: A clinical-stage, CNS-targeted oligonucleotide therapeutic for amyotrophic lateral sclerosis (ALS). Phase 1 clinical data demonstrated robust SOD1 protein knockdown (~60% CSF SOD1 reduction) and a favorable safety profile, with Phase 2 patient enrollment now fully completed.

Reflecting the global commercial value of its platform, Ractigen entered into a strategic drug discovery and platform licensing collaboration with a publicly listed overseas pharmaceutical company in late 2025, valued at over $3 billion.

Executive & Investor Commentary

Dr. Long-Cheng Li, Founder and Chief Executive Officer of Ractigen Therapeutics:
“Closing this financing round reflects strong capital market validation of Ractigen’s critical leap from pioneering scientific discovery to human clinical proof-of-concept. Over the past decade, the oligonucleotide field achieved tremendous commercial success in liver-targeted silencing, yet extrahepatic delivery and gene activation remained unaddressed global frontiers. Over nearly two decades, we progressed from discovering RNA activation to solving extrahepatic delivery bottlenecks and translating multiple assets into positive human clinical data. Moving forward, Ractigen will continue expanding the boundaries of RNA technology, accelerating clinical translation to deliver transformative, First-in-Class therapeutics to patients worldwide.”

Investment Team, Guozhong Capital:
“Ractigen Therapeutics is dedicated to pioneering next-generation RNA therapeutics globally. Its proprietary extrahepatic delivery platforms breach core bottlenecks across the field. RAG-17 is a pioneering CNS-targeting oligonucleotide therapy with Phase 1 results featured in top-tier peer-reviewed journals, while RAG-01 marks a historic clinical application of saRNA technology in oncology. We look forward to supporting Ractigen as its saRNA platform expands further into genetic, oncologic, and metabolic diseases.”

Haining Wang, Founding Partner of Longmen Capital:
“We have been a long-term believer in Ractigen since our initial investment in 2021, and this marks our third consecutive round of support. Their clinically validated extrahepatic delivery systems and highly differentiated saRNA pipelines create an unrivaled competitive moat. We will continue leveraging our industry and capital market resources to help Ractigen bring saRNA therapies to patients globally.”

About Ractigen Therapeutics

Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on saRNAs developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary extrahepatic delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing severe unmet medical needs in oncology, neurological diseases, and genetic disorders. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of targeted RNA activation and delivery. For more information, visit www.ractigen.com.

 

1...727374...6,441Page 73 of 6,441